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Abstract
Ovarian cancer (OC) is the leading cause of death from gynaecological cancer. It is extremely hard to diagnose in the early stages and 
around 70% of patients present with advanced disease. Metronomic chemotherapy (MCT) is described as the chronic administration of, 
generally low, equally spaced, doses of chemotherapeutic drugs with therapeutic efficacy and low toxicity. This is an effective and low-cost 
way to treat several types of tumours, including ovarian cancer. Here, we present six cases of advanced ovarian cancer treated with MCT 
with low doses of cyclophosphamide, which showed clinical response and stable disease. 
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Introduction
Ovarian cancer (OC) is the leading cause of death from gynaecological cancer in the United States, and accounts for 5% of cancer deaths 
among women, causing more deaths than any other gynaecological cancer. Unfortunately, less than 40% of women with ovarian cancer 
are cured [1]. In Argentina, OC is the fifth most common cancer in women, with approximately 2300 new cases per year, and it represents 
the sixth leading cause of cancer mortality in women [2]. The incidence of OC increases with age and it is higher in the sixth and seventh 
decade of life [3].
OC is extremely hard to diagnose in the early stages [4]. While most of the patients who are diagnosed with ovarian cancer at the early 
stages are asymptomatic, when clinical symptoms appear, patients have already developed middle- to late-stage tumours. Around 70% of 
patients present with advanced disease; the stage of the tumour when it is diagnosed as extremely important, because the 5-year survival 
is about 92% for the early stages, while it decreases to 18% for stage IV [5].
For non-metastatic OC, surgery remains the most important treatment, followed or not by adjuvant treatment with intravenous (IV) or intra-
peritoneal (IP) chemotherapy with platinum and taxanes [6–8]. The overall survival achieved with IP paclitaxel/cisplatin is longer than that 
obtained with IV paclitaxel/cisplatin in patients with optimal cytoreductive surgery [9]. Schemes with carboplatin have been demonstrated 
to be effective in patients with poor performance status [10]. 
Other treatment regimens for OC have been proposed, like hormone treatment [11], or targeted therapies using bevacizumab. However, the 
benefits of bevacizumab treatment are in question [12].
Low-dose metronomic chemotherapy (MCT) described as the administration of chronic, equally spaced and, generally, low doses of 
chemotherapeutic drugs without extended rest periods, that allows chronic treatment with therapeutic efficacy and low toxicity, has been 
demonstrated to be effective in several types of tumours (breast, sarcoma, lung, prostate), the decrease in vascular endothelial growth 
factor being one of the demonstrated mechanisms of action [13–16], which results in an antiangiogenic effect. Besides, MCT has been 
proved to modulate the host immune response; this effect is important considering that the anticancer immune response may be crucial 
for the long-term control of cancer. MCT can tilt the balance from immunosuppression to immunostimulation by several mechanisms, 
such as induction of immunogenic cancer cell death, enhancement of antigen presentation by dendritic cells, increase in cancer cells 
immunogenicity, depletion of regulatory T cells and modulation of myeloid-derived suppressor cells, enhancement of the cytotoxic activity 
of immune effector cells like tumour-specific T cells and γδT cells [17]. Moreover, since OC is strongly immunogenic, the therapeutic utility 
of immune checkpoint inhibitors, which would be able to overcome the tumour immune escape, is being explored [18]. Regulatory T cells 
(Tregs) is consider a poor prognosis factor. Interestingly, low doses of Cy administered metronomically have shown to decrease the level 
of Treg cells in tumour infiltrates [19, 20].
Another benefit described for MCT is the improvement of patients´ quality of life (QOL) or, at least, the absence of adverse changes in 
QOL [21].
At present, there are not many MCT trials involving OC, and most of the literature deals with case reports, or retrospective studies. In this 
case series report, we describe the evolution of six patients with advanced OC treated with metronomic cyclophosphamide as a palliative 
treatment.
Methods and case report
Six patients from the Italian Hospital of Rosario with advanced metastatic disease, refractory to standard chemotherapy, who were treated 
with metronomic cyclophosphamide were reviewed. The cases herein reported are consecutive and the total number of OC patients treated 
with MCT between 2012 and 2016 in the Italian Hospital of Rosario. The treatment selection was according to the attending doctor decision. 
Responses were evaluated using RESIST 1.1 and disease control was done using CT scan or MRI. Table 1 shows a summary of the main 
findings for each patient. Table 2 shows the treatments received and the PFS for each one.
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Table 1. Patient characteristics summary.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Age at diagnosis (years) 63 55 57 56 52 54
Age at MCT (years) 66 63 63 59 56 57
Diagnosis Endometrioid 
adenocarcinoma
Endometrioid 
adenocarcinoma
Papillary  
adenocarcinoma
Papillary  
adenocarcinoma
Endometrioid 
adenocarcinoma
Papillary  
adenocarcinoma
Stage at diagnosis IIIC IIIC IIIC IIIC IIIC IIIC
Stage at MCT IIIC IV IV IIIC IV IV
No of previous lines of  
chemotherapy 2 3 4 3 3 2
IP/HIPEC No/Yes No/No No/No Yes/No No/No Yes/No
Hormone therapy No Yes Yes No No Yes
Metastatic sites Intra-abdominal Lung, liver Lung, liver Pelvic, regional Hepatic, pelvic Hepatic
 Mean PFS (months)* 13.5 24,5 18 6 7 11 
PFS with MCT (months) 17 24 20 6 21 12
Best clinical response with MCT nPCR SD SD SD SD SD
Performance Status (ECOG) 
prior/post MCT 3/1 2/1 1/1 2/2 1/1 2/2
MCT: metronomic chemotherapy; IP: intra-peritoneal chemotherapy; HIPEC: hyperthermic intra-peritoneal chemotherapy. PFS: progression-free survival. 
* mean PFS calculated with the PFS of each line of standard treatment.
Table 2. Treatments summary.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
First line of  
treatment C + P IV × 6 cycles C + P IV × 6 cycles C + P IV × 6 cycles C + P IP × 6 cycles* C + P IV × 6 cycles C + P IV × 6 cycles
PFS (months) 16 37 26 4 14 19
Second line of 
treatment
C + P IV × 6 cycles 
+ HIPEC
Tamoxifen
C + P IV × 6 cycles 
+ Tamoxifen
LSD
Carboplatin  
monodrug **
Cisplatin IP
PFS (months) 11 36 24 6.6 2 9
Third line of  
treatment
MCT Cy 50 mg 
p.o.d
C + P IV × 6 cycles
Carboplatin mono-
drug
Carboplatin mono-
drug
LSD Tamoxifen 
PFS (months) 17 (OG) 12 11 7 5 5
Fourth line of  
treatment LSD LSD
MCT Cy 50 mg 
p.o.d
MCT Cy 50 mg 
p.o.d
MCT Cy 50 mg p.o.d
PFS (months) 13 10 6 21 (OG) 12
Fifth line of  
treatment MCT Cy 50 mg 
p.o.d
MCT Cy 50 mg 
p.o.d
Carboplatin,  
gemcitabine +  
bevacizumab
PFS (Months) 24 20 N/A
Sixth line of  
treatment
Topotecan +  
Bevacizumab
LSD
PFS (Months) 2 N/A
*Patients treatment with IV schemes finished due to complications with the port. 
**Patient presented severe anaphylactic reaction, and treatment was stopped. 
OG: on going. C+P: carboplatin + paclitaxel; MCT: metronomic chemotherapy; LSD: liposomal doxorubicin; N/A: not available.
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Patient 1: A 63-year-old female, with no background of serious diseases, who consulted for pain, abdominal distention, and ascites, was 
diagnosed a stage IIIC poorly differentiated ovarian endometrioid adenocarcinoma in July 2011. The preoperative level of cancer anti-
gen-125 (CA125) was 200.6 U/ml. The surgeon performed a R0 resection and then she received standard chemotherapy. After relapse, 
and due to the patient condition, low doses of cyclophosphamide (Cy) were considered. She received MCT with Cy (50 mg per oral, once 
daily -p.o.d-) since October 2014 and she is still on treatment; CA125 levels began a slow decrease, reaching normal values after 4 months 
of treatment. After 17 months of MCT a control MRI showed a major partial response (Figures 1 and 2). The patient is still under low doses 
of Cy, with good tolerance to medication and good QOL.
Patient 2: A 55-year-old female was diagnosed with bulky stage IIIC ovarian endometrioid adenocarcinoma. Pre-operative CA-125 was 114 
U/ml. The patient was treated with neo adjuvant chemotherapy and then, R0 resection surgery. Due to a significant decrease in her QOL 
in the fourth relapse (3 lines of chemotherapy and hormonal treatment) she started MCT with Cy (50 mg p.o.d). CA125 levels decreased 
from 55 U/ml to 9 U/ml in 5 months. Treatment was well tolerated with clinical improvement and weight gain. She received MCT from 
February 2014 to February 2016. After almost 24 months of treatment with stable disease, the patient progressed and she was switched 
to topotecan+bevacizumab, with very bad tolerance, deterioration of QOL and without therapeutic response. The patient is still alive in pal-
liative care at the moment. 
Figure 1. Pelvic magnetic resonance imaging using diffusion-weighted image. (A) Solid tumour lesion (arrow) of 2 cm pararectal space left rear; 
(B) a 2.2 cm tumour lesion in left paracolic pit. Both with enhancement in the diffusion restriction sequences; (C and D) after MCT, there are no 
signs of those lesions.
Figure 2. Contrast-enhanced pelvic magnetic resonance imaging. Previous MCT: (A) a 2.1 cm solid tumour in left paracolic grave, the tumour 
appears in close association with the rear edge of descendent colon and the left latero-conus fasia; (B) a 2.6 cm × 2.8 cm solid tumour lesion 
in contact with sigmoid colon; (C) a 2 cm tumour lesion in the pararectal space left rear. A, B, and C showed contrast enhancement after 
intravenous administration of gadolinium. After MCT: (D) no lesion in the left paracolic grave (arrow); (E) residual tumour lesion without diffuse 
heterogeneous enhancement with intravenous administration of gadolinium (arrow); (E) no lesion observed in the pararectal space (arrow).
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Patient 3: A 57-year-old woman was diagnosed with a stage IIIC epithelial ovarian cancer. Pre-operative CT showed ascites and abdomi-
nal mass. Pre-operative CA125 was 800 U/ml; she underwent optimal cytoreductive surgery and adjuvant chemotherapy. Due to progres-
sion, she received four lines of chemotherapy before MCT. She began metronomic Cy (50 mg p.o.d) after increase in the size of hepatic 
metastasis. CA125 decreased without reaching normal levels (values from 45 to 60 UI/ml). The patient recovered from the toxicity of 
the last chemotherapy treatment, kept working and had a normal way of living. Transient Cy dose reductions were indicated, due to G1 
haematological toxicities. CT scans showed stable disease. She received MCT from March 2012 to November 2013. Progression was 
detected after 20 months of treatment. The patient was lost to follow-up.
Patient 4: A 56-year-old female, with no background of serious diseases, was diagnosed stage IIIC poorly differentiated infiltrating papil-
lary adenocarcinoma of the ovary. Surgical exploration confirmed ascites and positive peritoneal implants. R0 Resection surgery was 
performed. Pre-operative level of CA125 was 16,860.6 U/ml. She received initial standard chemotherapy with early recurrence and two 
additional lines of chemotherapy, showing minor responses and rapid progression. With an inoperable pelvic mass and poor performance 
status, she started MCT (Cy, 50 mg p.o.d). The treatment elapsed with minimal toxicity, and ascites was controlled with diuretics. The 
patient’s condition remained stable with ECOG 2 for 6 months, after which she worsened gradually and died because of pleural effusion 
and lung metastasis.
Patient 5: A 52-year-old female, with a background of hypothyroidism, presented with abdominal distention and a pelvic tumour in a CT 
scan. She was diagnosed with a stage IIIC infiltrating endometrioid ovarian adenocarcinoma. She received surgery and standard chemo-
therapy with a total of three lines of treatments. After progression, she started MCT Cy (50 mg p.o.d) with a minimal hematological toxicity. 
MCT began in September 2014 with no interruptions and, at present, the patient continues the treatment. The patient’s condition remained 
stable with good QOL (ECOG 1). The patient is still alive (June 2016) with 21 months of PFS at the moment of manuscript writing. 
Patient 6: A 54-year-old woman was diagnosed with a stage IIIC papillary ovarian adenocarcinoma. Pre-operative CA125: 1648 U/ml; she 
underwent optimal cytoreductive surgery and received adjuvant chemotherapy. She received two lines of chemotherapy, a new surgery of 
the peritoneal masses and hormonal treatment before MCT. She was treated with MCT (Cy 50 mg p.o.d) with good tolerance and stable 
disease for 12 months. She received MCT from December 2013 to December 2014. After that period, the tumour progressed and she 
began a scheme with targeted therapy (bevacizumab) plus chemotherapy with partial response, severe toxicity and rapid progression. The 
patient is still alive and is under liposomal doxorubicin (LSD) chemotherapy at the moment of manuscript writing. 
Discussion
Here, we present six patients with metastatic OC in which metronomic Cy provided prolonged stable disease, clinical benefit, and one case with 
near clinical complete response. 
The use of platins and taxanes has improved the overall survival for OC. The outcomes depend not only on the chemotherapy schemes, but 
also on others factors like response to first line chemotherapy, disease free survival upon surgery, and number of previous treatments [22].
Metronomic chemotherapy with low doses of Cy has been proposed as a potential treatment of OC due to its antiangiogenic and immuno-
modulating properties [17]. However, the clinical trials that support this approach are scarce, and most of the information comes from case 
reports [23] and pre-clinical studies. Merritt et al., in a OC pre-clinical model, described that metronomic topotecan has antiproliferative 
effect and targets some pro-angiogenic mediators like Hif-1 alfa, suggesting it as a novel therapeutic strategy [24]. Likewise, the use of 
nabpaclitaxel and metronomic topotecan showed significant reductions in tumour weight and proliferation as well as pazopanib did. Those 
agents seem to be ideal for clinical trials [25, 26]. On the other hand, regarding the resistance to the drugs administered metronomically in 
different types of tumours, including OC, Chow et al suggested that the sensitivity to MCT using different drugs do not only depends on the 
antiangiogenic mechanism, but also on other unknown additional mechanisms that could be drug-specific [27].
One of the most controversial topics in OC is the use of antiangiogenic/target drugs. The combination of bevacizumab with carboplatin/
paclitaxel is associated with longer disease-free survival than the combination alone. But no significant difference has been observed 
in terms of overall survival rate [28]. Also, the use of bevacizumab as a maintenance drug subsequent to chemotherapy has not offered 
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benefits in survival, resulting in the addition of many side effects, and the increase in the treatment costs [29]. Since the evidence shows 
that bevacizumab does not appear to confer any survival advantage, the National Comprehensive Cancer Network panel does not recom-
mend its use.
In the clinical field, two retrospective studies analysed the role of MCT in OC. Sánchez-Muñoz et al suggested that the combination of 
metronomic oral Cy plus bevacizumab in heavily pretreated patients with recurrent OC could be an option, with a response rate of 40% 
and a Clinical Benefit of 48% [30]. Also, Ferrandina et al showed the efficacy and safety of metronomic oral Cy in heavily treated relapsed 
OC; the patients responding to MCT showed higher PFS and OS compared to those who had stable disease or disease progression [31]. 
Moreover, a case report by Samaritani et al presented a patient with stage-IIIC OC treated with metronomic Cy, who showed an impres-
sive PFS of 65 months, without side effects, after non-response to standard chemotherapy with platins, taxans, and topotecan [23]. Those 
results are very encouraging and the prolonged PFS accomplished agrees with the ones herein described. The non-randomized clinical 
trial conducted by El-husseiny et al, setting metronomic Cy and methotrexate as maintenance therapy in patients who achieved complete 
response after platinum and paclitaxel regimens, showed that the PFS was significantly higher (18 months) in the treatment arm than that 
of the observational one (15 months). Also, no grade III–IV toxicities were observed and the treatment regimen was safe and well tolerated 
[32]. Furthermore, the addition of bevacizumab (10 mg/kg) IV every two weeks to metronomic oral Cy 50 mg/d in recurrent OC showed a 
median PFS of 7.2 months, with mild toxicity [33]. 
It is well known that angiogenesis plays an important role in tumour growth and dissemination, and it is a key process in OC progression 
[15]. However, its intended inhibition with bevacizumab has not achieved the main objective, neither for adjuvant nor for maintenance or 
metastatic settings, causing serious side effects and increasing the costs of patient care. Some single and series case reports described 
the benefit of adding bevacizumab to MCT with Cy [34–36]; and one retrospective review describe that the addition of Cy to intravenous 
bevacizumab in heavily pre-treated patients with recurrent ovarian carcinoma improved PFS and OS in responders. However, the adverse 
events are not well described [37, 38]. Also, the cost-effective ratio of bevacizumab in OC is not totally clear [39], as well as the combination 
of bevacizumab with metronomic Cy. Hence, well designed clinical protocols are needed to clarify this matter. 
One important aspect to highlight is that MCT did not add toxicity in our patients, or did not worsen the QOL. Unfortunately, along with 
the scarcity of clinical trials of MCT for OC, there are no objective evaluations concerning QOL. As mentioned before, platin and taxanes 
have been intensively used in the treatment of ovarian cancer. Interestingly a study population using metronomic weekly paclitaxel plus 
carboplatin showed to be effective and well tolerated in those patients who did not tolerate the standard 21-day treatment [40].
Our results in this cohort of patients showed that the median PFS obtained with MCT-based chemotherapy (16.6 months) was slightly 
higher than that obtained with all of the previous standard treatments administered to those patients (13.3 months), with the advantage 
of low toxicity and its positive influence on QOL, suggesting that MCT could be utilized as an early treatment option for patients with 
recurrent disease. 
On the other hand, patients with endometrioid adenocarcinomas (3/6) showed a higher mean PFS (20.6 months) than that of patients with 
papillary adenocarcinoma (12.6 months -3/6), both in the metronomic-based chemotherapy, suggesting that the antiangiogenic properties 
of MCT would be more specific and sensitive for the endometrioid type of OC. Bamberger et al sustained that VEGF could be a useful 
marker of angiogenesis and tumour progression and that it is involved in ascites formation. Also, they affirm that, in spite the fact that 
tumour microvessel density is a prognostic factor in various types of cancer, apparently, in OC there is no correlation between that density 
and age, tumour size, ascites, or tumour growth [41]. Furthermore, up to this moment, there are no studies on the effect of MCT in different 
types of OC. 
In conclusion, OC represents a challenge for medical oncologists, in part for the high frequency of advanced disease at diagnosis, and 
also because of the lack of better systemic treatment approaches. Surgery, platins, and taxanes represent the keystones in the benefits 
for survival. Other chemotherapeutics schedules are toxics and did not demonstrate overall survival benefits. The use of old approved 
non-anticancer drugs for treating cancer is an attractive strategy to offer the patients more therapeutic options. The concept behind this 
strategy was developed by researchers integrating the Repurposing drugs in oncology (ReDO) Project [42]. Metronomics, a term coined by 
N. André et al refers to “all anticancer treatment regimens combining metronomic chemotherapy and drug repositioning”. Metronomics has 
gained importance, mainly for healthcare systems with budgets that do not support high-cost new oncology drugs [43, 44]. Studies utilising 
metformin [45], itraconazole [46], celecoxib [13], propranolol [47], clarithromycin [48], etc. have demonstrated the validity and potential of 
this therapeutic approach. 
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Conclusions
In summary, based on the clinical responses obtained and the low toxicity of the treatment, metronomic chemotherapy and drug repurposing 
are options to be taken into account for OC therapeutics. Clinical trials are needed to corroborate these findings.
• The treatment with low doses of cyclophosphamide resulted in therapeutic response which varied from near clinical complete 
response to long stable disease.
• Metronomic chemotherapy could be a feasible treatment option for ovarian cancer patients.
• Metronomic chemotherapy with oral cyclophosphamide presented a low toxicity profile and did not affect the patient’s quality of life.
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